Applications of Raltegravir in Industrial Manufacturing

Raltegravir is a high-value antiretroviral raw material with established utility across the pharmaceutical sector, particularly for active pharmaceutical ingredient (API) production and related intermediate synthesis. As a vertically integrated manufacturer, we ensure tight control over upstream and downstream quality, enabling reliable performance in each specific area described below.

1. Antiretroviral API Production for HIV-1 Integrase Inhibitors

Major pharmaceutical producers use our Raltegravir for direct formulation of APIs targeting HIV-1 integrase. The chemical enters the production process during the core tableting or encapsulation stages following micronization and blending with excipients. Its purity profile and lot-to-lot consistency ensure batch records align with strict regulatory filings in both US and EU markets. Our support includes validated analytical methods and comprehensive documentation for regulatory submissions in large-scale drug substance operations. Production environments demand controlled humidity and temperature to maintain stability and avoid degradation of the active moiety during the downstream process, with distributed quality controls from raw material release to finished dosage form.

Industry compliance standards

• USP (United States Pharmacopeia) Raltegravir Monograph
• EP (European Pharmacopoeia) Raltegravir standards
• ICH Q7 Good Manufacturing Practices for APIs
• US FDA cGMP for finished pharmaceuticals (21 CFR Part 211)

Typical usage ratio

• Active ingredient concentration in final tablets: 400 mg/tablet (core, blend formulation)
• Formulation ratio: 20–35% by weight relative to total tablet blend, adjusted per required dose

Downstream process integration

• Direct addition during dry blending and granulation
• Integrated into wet granulation processes prior to tableting or encapsulation
• In-process control sampling for assay and uniformity prior to compression
• Stabilization with functional excipients for moisture protection

Final product types

• HIV-1 integrase inhibitor tablets (400 mg, 600 mg presentations)
• Oral film-coated solid dosage forms
• Fixed dose combination tablets (with NRTIs or other ARVs)

2. Fixed Dose Combination (FDC) Antiretroviral Formulation Manufacturing

Our Raltegravir serves as a core component in the downstream development of fixed dose combinations (FDCs) vital for combination antiretroviral therapy. Major FDC manufacturers blend it with nucleoside reverse transcriptase inhibitors (e.g., lamivudine, tenofovir) using low-shear or high-shear blending techniques. Producers implement rigorous blending validation and segregation parameters to prevent cross-contamination, particularly critical when handling multipurpose facilities. The adjustment of Raltegravir’s ratio depends on synergistic antiviral profiles and approved therapeutic indications, requiring close coordination between our process chemists and FDC clients’ formulation scientists. Special consideration in wet and dry granulation steps minimizes segregation and maintains content uniformity across large batch sizes.

Industry compliance standards

• WHO Prequalification Program for Antiretroviral APIs and FDCs
• US FDA cGMP for combination drug products
• EMA Guideline on Fixed Combination Medicinal Products
• ICH Q8 (Pharmaceutical Development)

Typical usage ratio

• Raltegravir proportion: 20–30% of core tablet mass depending on FDC strength (typically 300–600 mg per unit)
• Ratio adjusted based on co-formulated agents and regulatory label requirements

Downstream process integration

• Incorporation during pre-mixing with other active ingredients under controlled conditions
• Dispersal using high-shear granulation equipment to maintain blend uniformity
• Sequential layer compression for bilayer or trilayer tablets where physical separation of APIs is needed
• Sampling during compression stage for multi-component content assay checks

Final product types

• Fixed Dose Combination tablets including Raltegravir with NRTI/NNRTI partners
• Multilayer oral solid drugs for adult and pediatric HIV treatment

3. Active Pharmaceutical Ingredient (API) Intermediate Synthesis & Bulk Supply

Several leading pharmaceutical groups source our Raltegravir as an intermediate in the manufacturing pathway for downstream finished products. Process engineers typically receive the crystalline intermediate in bulk containers designed for compatibility with cGMP transfer systems. Our bulk Raltegravir integrates with automated feeding lines and closed-system reactors to reduce operator exposure and maintain containment. Downstream QA teams use our supplied analytical documentation to verify identity, impurity profile, and residual solvent content, aligning with stringent import testing on both domestic and international distribution channels. Our robust consistency in physical and chemical specifications meets the critical reproducibility requirements for high-volume pharmaceutical synthesis operations.

Industry compliance standards

• ICH Q3A/B (Impurities in New Drug Substances and Products)
• USP–NF General Notices & Requirements (Identity and Purity)
• EU GMP Volume 4 Part II for starting materials
• China Pharmacopoeia (when supplied for Chinese drug manufacturing)

Typical usage ratio

• Intermediate Raltegravir loaded per batch: 5–30 kg (lot size based on client synthesis scale)
• Active fraction typically constitutes 100% of the batch intermediate charge (no blending at this stage)

Downstream process integration

• Conveyed into synthesis vessels for salt-formation, micronization, or co-crystal production
• Automated transfer into pre-processing nodes for final purification or crystallization steps
• Subject to in-line NIR and HPLC verification on transfer
• Batch documentation linked via electronic batch record systems

Final product types

• API-grade finished materials for oral dosage drugs
• High-purity intermediates for further downstream derivatization

4. Reference Standard Preparation for Analytical Method Development

Pharmaceutical QC laboratories and contract research organizations rely on precisely characterized Raltegravir bulk material as certified primary or secondary reference standards. These standards play a key role in validating HPLC, UPLC, and mass spectrometry assay methods for ongoing drug release and stability testing. Users depend on our controlled manufacturing environment and exhaustive documentation—covering spectral fingerprint, polymorph analysis, and stability data—to maintain traceable reference materials. This dataset ensures easy alignment with regulatory method validation dossiers for both generic and branded finished dosage manufacturers, and allows downstream users to maintain calibration traceability in their validated analytical protocols.

Industry compliance standards

• ISO 17034 (General requirements for the competence of reference material producers)
• USP/EP Reference Standard Policies
• Good Laboratory Practice (GLP) guidelines for pharmaceutical analytical testing
• Pharmacopeial standards for API reference material characterization

Typical usage ratio

• Standard addition for assay development: 1–5 mg per analytical run
• Periodic batch change every 12–24 months aligned to validated method requirements

Downstream process integration

• Direct portioning into QC analytical test methods (HPLC, UPLC, LC-MS)
• Used for periodic calibration and re-validation procedures
• Stabilization in amber vials, often under inert gas, to prevent degradation
• Recorded into LIMS (Laboratory Information Management Systems) for full material traceability

Final product types

• Certified chemical reference standards for pharmaceutical laboratories
• Primary and secondary reference vials for regulatory and in-house method validation